Rochester / Buckinghamshire / Houston / New York / Laemmli / Tokyo / Dassel / Washington / D.C. / Louis / Prague / Amsterdam / Aviano / Meriden / St. Louis / /
Company
Sigma Chemical Co. / Kodak / IgG / Eastman Kodak Co. / D.L. Cherwitz N.A. / Spectrum Medical Industries Inc. / Pharmacia Diagnostics AB / IOS Press / Amersham International / Flow Laboratories Inc. / Jackson ImmunoResearch Laboratories Inc. / DAKO A/S / D.A.S. / Schleicher & Schuell Inc. / Clinical Investigation Inc. / /
Country
Germany / Romania / Italy / Sweden / United States / United Kingdom / Denmark / Czech Republic / /
Currency
USD / / /
Event
FDA Phase / M&A / /
Facility
University of Cambridge / Institute of Molecular Genetics / Memorial Sloan-Kettering Cancer Center / Institute of Oncology / / /
IndustryTerm
cancer therapy / conditioned media / cellular and humoral immune systems / treatment of human melanoma / treatment of Mel 116 and Mel 97 melanoma / /
MedicalCondition
CD59-positive human melanoma / investigated melanoma / neurological disorders / CD59-positive melanoma / human malignant gliomas / human melanoma / melanoma / multiple sclerosis / CD59-negative melanoma / 51Cr-labeled CD59-negative MeWo melanoma / colonic adenocarcinoma cells / Human carcinomas / human breast cancer / MeWo melanoma / CD59-negative MeWo melanoma / tumor / cultured melanoma / additional melanoma / Cancer / disease / human malignant melanoma / noma cells / J. Cancer / infectious conditions / mela1254 Brasoveanu et al. noma / malignant melanoma / cutaneous melanoma / malignant gliomas / carcinomas / allogeneic melanoma / T cell/tumor / different melanoma cells / inflammatory / metastatic melanoma / melanoma cells / /
MedicalTreatment
immunotherapy / cancer therapy / dialysis / /
Organization
American Society for Clinical Investigation / Department of Pathology / Italian Ministry of Public Health / Institute of Molecular Genetics / University of Cambridge / Memorial Sloan-Kettering Cancer Center / Homologous Complement-mediated Cytotoxicity Lorelei I. Brasoveanu / * Ester Fonsatti / * Alberto Visintin / * Mirjana Pavlovic / * Ilaria Cattarossi / * Francesca Colizzi / * Aldo Gasparollo / * Sandra Coral / * Vaclav Horejsi / ‡ Maresa Altomonte / * and Michele Maio* *Advanced Immunotherapy Unit / Advanced Immunotherapy Unit / Institute of Oncology of Bucharest / NHS / /
Person
M. Maio / R. Tatake / A. Gloghini / Staley / Sandra Coral / Vaclav Horejsi / ‡ Maresa / Ilaria Cattarossi / I. Cattarossi / Peter Lachmann / F. Indiveri / M.R. Nicotra / Mirjana Pavlovic / R.A. Zeff / M. Altomonte / Francesca Colizzi / A. Gasparollo / A. Cattelan / D.J. Knapp / G. Bertola / S. Ferrone / A. Carbone / A. Visintin / M.B. Hallett / V / Michele Maio / Alan Houghton / G. Esposito / P.G. Natali / M. Scudeletti / A.P. Dalmasso / Aldo Gasparollo / F. Colizzi / / /
Position
editor / RT / Fisher / and S. Ferrone / representative data demonstrating / representative / Data representative / head of bacteriophage T4 / /
Melanoma Cells Constitutively Release an Anchor-positive Soluble Form of Protectin (sCD59) That Retains Functional Activities in Homologous Complement-mediated Cytotoxicity Lorelei I. Brasoveanu,* Ester Fonsatti,* Albert